Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-permanent) Atrial Fibrillation and Left Atrial Flutter

Trial Profile

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-permanent) Atrial Fibrillation and Left Atrial Flutter

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Feb 2017 Planned End Date changed from 1 Oct 2016 to 1 Jun 2017.
    • 14 Dec 2015 Planned number of patients changed from 100 to 101 as reported by ClinicalTrials.gov.
    • 14 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top